News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pluristem Therapeutics (PSTI) to Initiate a Phase I/II Clinical Trial in Muscle Injury


11/14/2012 7:30:53 AM

HAIFA, Israel, Nov. 14, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has initiated a Phase I/II clinical trial to evaluate the safety and efficacy of its PLacental Expanded (PLX) cells in the treatment of muscle injury. As previously reported, the Paul Ehrlich Institute (PEI), the German competent authority in the European Union, has granted the Company clearance to start the trial which will be conducted at the Klinik für Orthopadie on the campus of the Charité Universitatsmedizin in Berlin, Germany.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES